ACRP CRC TEST BANK FINAL EXAM 2026-2027
Exam || Latest Exam With Actual Complete
Real Questions And Correct Answers (Verified
Answers) Already Graded A+ | Guaranteed
Success!! Newest Exam | Just Released!!
In ascertaining the basis for a serious adverse drug reaction in a
randomized trial:
a) Care should be taken not to break the blind for the patient.
b) Care should be taken to break the blind only for the single
patient involved.
c) The blind for the group of patients being treated at the site
should be broken.
d) The blind for the single patient should be broken only if the
sponsor approves.
b) Care should be taken to break the blind only for the single
patient involved
,Breaking the blind for a single patient in randomized clinical trial:
a) Has negative implications for data integrity at the site level.
b) Has little or no significant implication for the investigation or
financial data analysis.
c) May compromise drug approval because of implications for
financial data analysis.
d) Provides no significant information regarding the safety of the
patient.
b) Has little or no significant implication for the investigation or
financial data analysis.
Adverse drug reactions in the control group should be reported to:
a) The other manufacturer
b) Appropriate regulatory agency
c) A only
d) A and B
d) A and B.
A) The other manufacturer
B) Appropriate regulatory agency
,An adverse reaction occurs in patients after the study has been
completed. The appropriate action on the part of the
investigatorinclude:
a) Report the event to the sponsor.
b) Consider the event for reporting as though it was a study report.
c) Conduct causality assessment and determination of
expectedness prior to expedited reporting.
d) All of the above
d) All of the above
A response to a medical product means (Select all that Apply):
a) A causal relationship between drug and adverse event
is established
b) A causal relationship between drug and adverse event is
a reasonable possibility
c) The relationship of the event to drug cannot be ruled out
d) An event that requires active medical intervention
b and c. B) A causal relationship between drug and adverse event
is a reasonable possibility and C) The relationship of the event to
drug cannot be ruled out.
, New safety information regarding a study drug should be updated
by the sponsor by:
a) Notifying the IRB
b) Notifying the investigator
c) Updating the protocol
d) Updating the Investigator's Brochure
d) Updating the Investigator's Brochure
An unexpected adverse drug reaction is a reaction:
a) Happens immediately after drug administration.
b) Is inconsistent with the documented product information in the
investigator's brochure or other source documents.
c) Known to occur frequently in preclinical studies.
d) Dependent on the dose of the drug
b) Is inconsistent with the documented product information in the
investigator's brochure or other source documents.
Exam || Latest Exam With Actual Complete
Real Questions And Correct Answers (Verified
Answers) Already Graded A+ | Guaranteed
Success!! Newest Exam | Just Released!!
In ascertaining the basis for a serious adverse drug reaction in a
randomized trial:
a) Care should be taken not to break the blind for the patient.
b) Care should be taken to break the blind only for the single
patient involved.
c) The blind for the group of patients being treated at the site
should be broken.
d) The blind for the single patient should be broken only if the
sponsor approves.
b) Care should be taken to break the blind only for the single
patient involved
,Breaking the blind for a single patient in randomized clinical trial:
a) Has negative implications for data integrity at the site level.
b) Has little or no significant implication for the investigation or
financial data analysis.
c) May compromise drug approval because of implications for
financial data analysis.
d) Provides no significant information regarding the safety of the
patient.
b) Has little or no significant implication for the investigation or
financial data analysis.
Adverse drug reactions in the control group should be reported to:
a) The other manufacturer
b) Appropriate regulatory agency
c) A only
d) A and B
d) A and B.
A) The other manufacturer
B) Appropriate regulatory agency
,An adverse reaction occurs in patients after the study has been
completed. The appropriate action on the part of the
investigatorinclude:
a) Report the event to the sponsor.
b) Consider the event for reporting as though it was a study report.
c) Conduct causality assessment and determination of
expectedness prior to expedited reporting.
d) All of the above
d) All of the above
A response to a medical product means (Select all that Apply):
a) A causal relationship between drug and adverse event
is established
b) A causal relationship between drug and adverse event is
a reasonable possibility
c) The relationship of the event to drug cannot be ruled out
d) An event that requires active medical intervention
b and c. B) A causal relationship between drug and adverse event
is a reasonable possibility and C) The relationship of the event to
drug cannot be ruled out.
, New safety information regarding a study drug should be updated
by the sponsor by:
a) Notifying the IRB
b) Notifying the investigator
c) Updating the protocol
d) Updating the Investigator's Brochure
d) Updating the Investigator's Brochure
An unexpected adverse drug reaction is a reaction:
a) Happens immediately after drug administration.
b) Is inconsistent with the documented product information in the
investigator's brochure or other source documents.
c) Known to occur frequently in preclinical studies.
d) Dependent on the dose of the drug
b) Is inconsistent with the documented product information in the
investigator's brochure or other source documents.
